| Not Yet Recruiting | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence NCT07495124 | University of Washington | Phase 2 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) NCT07480954 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer NCT06846424 | Shanghai Gynecologic Oncology Group | Phase 1 |
| Recruiting | REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors NCT06710548 | Dana-Farber Cancer Institute | N/A |
| Completed | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovar NCT06870539 | Mayo Clinic | — |
| Recruiting | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients Wit NCT06492070 | Emory University | Phase 2 |
| Recruiting | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973 | Peking University Cancer Hospital & Institute | Phase 2 |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Recruiting | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemo NCT05763199 | University of California, Davis | Phase 2 |
| Active Not Recruiting | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemothera NCT05406674 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Recruiting | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care NCT04834544 | Peking University Third Hospital | Phase 2 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy NCT04204811 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives NCT04257045 | M.D. Anderson Cancer Center | — |
| Recruiting | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma NCT06972693 | European Institute of Oncology | Phase 4 |
| Unknown | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epitheli NCT02033616 | Aivita Biomedical, Inc. | Phase 2 |
| Recruiting | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 NCT03296826 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | — |
| Completed | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian C NCT03297489 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Withdrawn | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer NCT02530606 | Stanford University | N/A |
| Completed | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer NCT02788708 | Floor Backes | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or NCT02584478 | Advenchen Laboratories, LLC | Phase 3 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Und NCT02315469 | NRG Oncology | — |
| Completed | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent NCT02344095 | Seoul National University Hospital | Phase 1 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With O NCT02166905 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Periton NCT02118285 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer NCT02199171 | University of California, Irvine | Phase 1 |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Unknown | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer NCT02125513 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 2 |
| Terminated | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma NCT01936974 | Western Regional Medical Center | Phase 2 |
| Unknown | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? NCT01611766 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Completed | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma NCT01519869 | Rachel Miller | Phase 2 |
| Unknown | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients Wit NCT02328716 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Phase 3 |
| Completed | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma NCT01381861 | Tracon Pharmaceuticals Inc. | Phase 2 |
| Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Perit NCT01295489 | Gynecologic Oncology Group | — |
| Withdrawn | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-01 NCT01445275 | Gynecologic Oncology Group | — |
| Completed | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, o NCT01118052 | Gynecologic Oncology Group | Phase 2 |
| Terminated | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer NCT01202890 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer NCT01139957 | Gynecologic Oncology Group | — |
| Completed | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Lin NCT01709487 | Jules Bordet Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Canc NCT01116648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary NCT00958698 | Gynecologic Oncology Group | N/A |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Prim NCT00939809 | Gynecologic Oncology Group | Phase 2 |
| Terminated | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Canc NCT01773889 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study NCT00968799 | Cantonal Hospital of St. Gallen | N/A |
| Withdrawn | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial NCT00551265 | Gynecologic Oncology Group | N/A |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovari NCT00499252 | Gynecologic Oncology Group | Phase 2 |
| Completed | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer NCT00880360 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopi NCT00301756 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, NCT00352300 | Gynecologic Oncology Group | Phase 1 |
| Completed | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ova NCT00066456 | Gynecologic Oncology Group | Phase 1 |
| Completed | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359 | Gynecologic Oncology Group | Phase 1 |